Search

Your search keyword '"Wei, Yaohua"' showing total 143 results
Start Over Author "Wei, Yaohua"
143 results on '"Wei, Yaohua"'

6. The challenge and opportunity of gut microbiota‐targeted nanomedicine for colorectal cancer therapy

Author

Wei, Yaohua, primary, Shen, Feng, additional, Song, Huidong, additional, Zhao, Ruifang, additional, Feng, Weiyue, additional, Pan, Yue, additional, Li, Xiaobo, additional, Yu, Huanling, additional, Familiari, Giuseppe, additional, Relucenti, Michela, additional, Aschner, Michael, additional, Shi, Hanping, additional, Chen, Rui, additional, Nie, Guangjun, additional, and Chen, Hanqing, additional

Published
2024
Full Text
View/download PDF

16. Hyaluronic Acid‐Guided Cerasome Nano‐Agents for Simultaneous Imaging and Treatment of Advanced Atherosclerosis

Author

Ma, Qian, primary, Wu, Sijing, additional, Yang, Ling, additional, Wei, Yaohua, additional, He, Chaoyong, additional, Wang, Wenshan, additional, Zhao, Yingxin, additional, Wang, Zhijian, additional, Yang, Shiwei, additional, Shi, Dongmei, additional, Liu, Yuyang, additional, Zhou, Zhiming, additional, Sun, Jiefang, additional, and Zhou, Yujie, additional

Published
2022
Full Text
View/download PDF

22. Delivery of Neutrophil Membrane Encapsulated Non-Steroidal Anti-Inflammatory Drugs by Degradable Biopolymer Microneedle Patch for Rheumatoid Arthritis Therapy

Author

Lin, Yixuan, primary, Chen, Yang, additional, Deng, Ronghui, additional, Qin, Hao, additional, Li, Nan, additional, Qin, Yuting, additional, Chen, Hanqing, additional, Wei, Yaohua, additional, Wang, Zeming, additional, Sun, Qing, additional, Qiu, Wenyi, additional, Shi, Jian, additional, Chen, Long, additional, Wang, Yuguang, additional, Nie, Guangjun, additional, and Zhao, Ruifang, additional

Published
2022
Full Text
View/download PDF

25. Hyaluronic Acid‐Guided Cerasome Nano‐Agents for Simultaneous Imaging and Treatment of Advanced Atherosclerosis.

Author

Ma, Qian, Wu, Sijing, Yang, Ling, Wei, Yaohua, He, Chaoyong, Wang, Wenshan, Zhao, Yingxin, Wang, Zhijian, Yang, Shiwei, Shi, Dongmei, Liu, Yuyang, Zhou, Zhiming, Sun, Jiefang, and Zhou, Yujie

Subjects
ATHEROSCLEROTIC plaque, ATHEROSCLEROSIS, MAGNETIC resonance imaging, INTRAVASCULAR ultrasonography, CAROTID intima-media thickness, HYALURONIC acid
Abstract

Early noninvasive screening and regression therapy for vulnerable atherosclerotic plaques remain challenging. In this study, it is aimed to develop a new approach for the active targeting of atherosclerotic plaques with nano‐agents to aid imaging and treatment. Biocompatible hyaluronic acid (HA)‐guided cerasomes are generated to selectively target CD44‐positive cells within the plaque in in vitro studies and in vivo testing in Apoe−/− mice. Rosuvastatin (RST) is encapsulated in the HA‐guided cerasome nano‐formulation to produce HA‐CC‐RST, which results in significant plaque regression as compared to treatment with the free drug. Moreover, gadodiamide‐loaded HA‐CC enhances magnetic resonance images of vulnerable plaques, thereby attaining the goal of improved simultaneous treatment and imaging. Transcriptomic analysis confirms plaque regression with HA‐CC–RST treatment, which potentially benefits from the anti‐inflammatory effect of RST. In summary, a safe and efficient nano‐formulation for the targeted delivery of active agents to atherosclerotic plaques is developed and may be applicable to other diagnostic and therapeutic agents for atherosclerosis treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor

Author

Zou, Yan, Wei, Yaohua, Sun, Yinping, Bao, Jie, Yao, Feirong, Li, Zekun, Meng, Fenghua, Hu, Chunhong, Storm, Gert, Zhong, Zhiyuan, Afd Pharmaceutics, Pharmaceutics, Biomaterials Science and Technology, Afd Pharmaceutics, and Pharmaceutics

Subjects
Male, Polymers, medicine.medical_treatment, Melanoma, Experimental, Medicine (miscellaneous), chemistry.chemical_element, reduction-sensitive, 02 engineering and technology, 010402 general chemistry, Iodine, 01 natural sciences, Peptides, Cyclic, Theranostic Nanomedicine, chemistry.chemical_compound, In vivo, medicine, Animals, Disulfides, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Chemotherapy, technology, industry, and agriculture, 021001 nanoscience & nanotechnology, In vitro, 0104 chemical sciences, Mice, Inbred C57BL, chemistry, Doxorubicin, polymersomes, Polymersome, CT imaging, Cancer research, Female, solid tumor, Trimethylene carbonate, Iohexol, Targeted delivery, 0210 nano-technology, Ethylene glycol, medicine.drug, Research Paper
Abstract

There is tremendous interest in integrating CT imaging with chemotherapy; however, reported iodine-based nanosystems such as nanogels and nano-emulsions display typically reduced contrast coefficient, low drug loading and stability, and poor targetability. Here, cRGD-functionalized disulfide-crosslinked iodine-rich polymersomes (cRGD-XIPs) were designed as a novel, robust and smart theranostic agent and investigated for targeted CT imaging and chemotherapy of malignant tumors. Methods: cRGD-XIPs were prepared from co-self-assembly of poly(ethylene glycol)-b-poly(dithiolane trimethylene carbonate-co-iodinated trimethylene carbonate) (PEG-P(DTC-IC)) and cRGD-PEG-P(DTC-IC) block copolymers. In vitro and in vivo CT contrast effect of cRGD-XIPs was studied using αvβ3-overexpressing B16 melanoma as a tumor model in comparison with clinical agent iohexol. The therapeutic efficacy of doxorubicin-loaded cRGD-XIPs (cRGD-XIPs-Dox) to B16 melanoma was investigated and compared with XIPs-Dox (non-targeted), cRGD-IPs-Dox (non-crosslinked) and free Dox. Results: cRGD-XIPs were formed with 55.5 wt.% iodine and ca. 90 nm in diameter. cRGD-XIPs-Dox with a Dox loading of 15.3 wt.% bared superior colloidal stability and reduction-responsive drug release. Notably, blank cRGD-XIPs showed a maximum-tolerated dose (MTD) > 400 mg iodine equiv./kg while cRGD-XIPs-Dox had an MTD > 150 mg Dox equiv./kg, ca. 15-fold improvement over free Dox. cRGD-XIPs revealed superior CT contrast effect and achieved 46.5- and 24.0-fold better enhancement of CT imaging of B16 melanoma than iohexol at 4 h following intratumoral and intravenous injection, respectively. cRGD-XIPs-Dox displayed an elimination half-life of 6.5 h and an elevated accumulation of 6.68% ID/g in the tumors. Furthermore, cRGD-XIPs-Dox was significantly more effective than XIPs-Dox and cRGD-XPs-Dox in inhibiting growth of B16 melanoma model. Conclusion: This proof-of-concept study demonstrates that cRGD-XIPs are a robust, non-toxic and smart polymeric theranostic agent that can not only significantly enhance CT imaging of tumors but also mediate efficient tumor-targeted chemotherapy. XIPs offer a unique and safe platform for theranostic polymersomes that pre-select patients using CT imaging prior to targeted chemotherapy with the same system.

Published
2019

32. α3β1 Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment

Author

Zou, Yan, Sun, Yinping, Guo, Beibei, Wei, Yaohua, Xia, Yifeng, Huangfu, Zhenyuan, Meng, Fenghua, van Hest, Jan C.M., Yuan, Jiandong, Zhong, Zhiyuan, Zou, Yan, Sun, Yinping, Guo, Beibei, Wei, Yaohua, Xia, Yifeng, Huangfu, Zhenyuan, Meng, Fenghua, van Hest, Jan C.M., Yuan, Jiandong, and Zhong, Zhiyuan

Abstract

Docetaxel (DTX) widely used for treating nonsmall cell lung cancer (NSCLC) patients is associated with dose-limiting side effects, especially neurotoxicity and myelosuppression. Here, we have developed cyclic cNGQGEQc peptide-directed polymersomal docetaxel (cNGQ-PS-DTX) as a targeted and multifunctional formulation for NSCLC. cNGQ-PS-DTX carrying 8.1 wt % DTX had a size of 93 nm, neutral surface charge, high stability, and glutathione-triggered DTX release behavior. Cytotoxicity studies demonstrated a clearly better antitumor activity of cNGQ-PS-DTX in α3β1 integrin overexpressing A549 human lung cancer cells than free DTX and nontargeted PS-DTX. cNGQ-PS-DTX showed a remarkably high tolerability (over 8 times better than free DTX) and slow elimination in mice. Importantly, cNGQ-PS-DTX exhibited greatly improved tumor accumulation and higher suppression of subcutaneous and orthotopic A549 xenografts as compared to PS-DTX and free DTX controls. α3β1 integrin-targeting polymersomal docetaxel emerges as an advanced nanotherapeutic for NSCLC treatment.

Published
2020

39. Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor

Author

Afd Pharmaceutics, Pharmaceutics, Zou, Yan, Wei, Yaohua, Sun, Yinping, Bao, Jie, Yao, Feirong, Li, Zekun, Meng, Fenghua, Hu, Chunhong, Storm, Gert, Zhong, Zhiyuan, Afd Pharmaceutics, Pharmaceutics, Zou, Yan, Wei, Yaohua, Sun, Yinping, Bao, Jie, Yao, Feirong, Li, Zekun, Meng, Fenghua, Hu, Chunhong, Storm, Gert, and Zhong, Zhiyuan

Published
2019

41. Nanopolymersomes with an Ultrahigh Iodine Content for High-Performance X-Ray Computed Tomography Imaging In Vivo

Author

Zou, Yan, Wei, Yaohua, Wang, Guanglin, Meng, Fenghua, Gao, Mingyuan, Storm, G, Zhong, Zhiyuan, Pharmaceutics, and Afd Pharmaceutics

Subjects
medicine.medical_specialty, Materials science, Blood pool, Iohexol, chemistry.chemical_element, Contrast Media, 02 engineering and technology, 010402 general chemistry, Iodine, 01 natural sciences, Mice, Materials Science(all), X ray computed, In vivo, medicine, Animals, General Materials Science, Medical physics, contrast agents, targeted imaging, Mechanical Engineering, computed tomography, Iodides, 021001 nanoscience & nanotechnology, Biocompatible material, 0104 chemical sciences, Nanostructures, chemistry, Mechanics of Materials, polymersomes, 2023 OA procedure, Tomography, 0210 nano-technology, Tomography, X-Ray Computed, Preclinical imaging, Biomedical engineering, medicine.drug
Abstract

Biodegradable nanopolymersomes with an ultrahigh iodine content for high-performance CT imaging in vivo were designed. To obtain iodine-rich nanopolymersomes, we devised and prepared a new iodine-functionalized trimethylene carbonate (IC) monomer in two straight steps with an overall yield of 25% by the Finkelstein reaction. Gel permeation chromatography displayed a unimodal distribution with a moderate Mw/Mn of 1.40, confirming successful synthesis of PEG-b-PIC. Interestingly, PEG-b-PIC had an ultrahigh iodine content of 60.4 wt%, which is significantly higher than iohexol and all reported iodinated nanoparticle platforms. Remarkably, the PEG-b-PIC diblock copolymer was readily self-assembled into stable nanopolymersomes. Dynamic light scattering (DLS) showed a small hydrodynamic size of =100 nm with a low polydispersity index =0.10. Transmission electron microscopy (TEM) image confirmed their small size and vesicle structure, likely due to their thick membrane and the inherent PEG stealth ability. The stability of iodine conjugated with an aliphatic chain is usually weaker than that conjugated with aromatic derivatives. However, unlike traditional small molecules, all iodine atoms in IPs are sequestered in the hydrophobic membrane of polymersomes, which would effectively protect iodine from leakage. The in vivo SPECT/CT images showed that in sharp contrast to fast accumulation of Na125I in the thyroid and bladder, I-labeled IPs had a long circulation time and predominantly accumulated in the RES like spleen and liver, further corroborating that IPs are stable in circulation and iodine leakage is negligible.

Published
2017

46. α3β1Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment

Author

Zou, Yan, Sun, Yinping, Guo, Beibei, Wei, Yaohua, Xia, Yifeng, Huangfu, Zhenyuan, Meng, Fenghua, van Hest, Jan C. M., Yuan, Jiandong, and Zhong, Zhiyuan

Abstract

Docetaxel (DTX) widely used for treating nonsmall cell lung cancer (NSCLC) patients is associated with dose-limiting side effects, especially neurotoxicity and myelosuppression. Here, we have developed cyclic cNGQGEQc peptide-directed polymersomal docetaxel (cNGQ-PS-DTX) as a targeted and multifunctional formulation for NSCLC. cNGQ-PS-DTX carrying 8.1 wt % DTX had a size of 93 nm, neutral surface charge, high stability, and glutathione-triggered DTX release behavior. Cytotoxicity studies demonstrated a clearly better antitumor activity of cNGQ-PS-DTX in α3β1integrin overexpressing A549 human lung cancer cells than free DTX and nontargeted PS-DTX. cNGQ-PS-DTX showed a remarkably high tolerability (over 8 times better than free DTX) and slow elimination in mice. Importantly, cNGQ-PS-DTX exhibited greatly improved tumor accumulation and higher suppression of subcutaneous and orthotopic A549 xenografts as compared to PS-DTX and free DTX controls. α3β1integrin-targeting polymersomal docetaxel emerges as an advanced nanotherapeutic for NSCLC treatment.

Published
2020
Full Text
View/download PDF

49. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma

Author

Li, Yingwen, Wei, Jingjing, Wei, Yaohua, Cheng, Liang, Guo, Beibei, Meng, Fenghua, Li, Feng, and Zhong, Zhiyuan

Abstract

Sorafenib (SF) is an FDA-approved molecular-targeted drug for treating hepatocellular carcinoma (HCC). SF, however, suffers from poor water solubility, low bioavailability, dose-limiting side effects, and possible drug resistance. Here, we report on apolipoprotein E peptide-decorated disulfide-cross-linked micellar SF (ApoE-Ms-SF) as a targeted and intelligent formulation for HCC therapy. ApoE-Ms-SF was prepared with a good SF loading of 7.0 wt %, small size (37 nm), high stability, and reduction-triggered drug release from poly(ethylene glycol)-b-poly(ε-caprolactone-co-dithiolane trimethylene carbonate)-mefenamate (PEG-P(CL-DTC)-MA) and ApoE-modified ApoE-PEG-P(CL-DTC) block copolymers. MTT assays in low-density lipoprotein receptors (LDLRs) overexpressing SMMC-7721 human liver cancer cells showed ApoE density-dependent antitumor potency of ApoE-Ms-SF, in which 7.5% ApoE led to the best antitumor effect (IC50: 8.5 vs 23.3 μg/mL for free SF). Confocal studies, flow cytometry, western blot, and apoptotic assays illustrated clearly a more efficient uptake of ApoE-Ms than nontargeted Ms by SMMC-7721 cells as well as lower phosphorylated extracellular signal-regulated kinase protein level and better cell apoptosis caused by ApoE-Ms-SF compared with Ms-SF and free SF. ApoE-Ms-SF revealed a long circulation time (elimination half-life = 6.8 h). DiR-loaded ApoE-Ms showed a significantly higher accumulation in SMMC-7721 tumor than the nontargeted counterpart. The therapeutic outcomes in the orthotopic SMMC-7721 tumor models demonstrated that ApoE-Ms-SF reduced SF-associated side effects and brought about enhanced angiogenesis inhibition and tumor apoptosis compared to free SF and Ms-SF controls, leading to a better treatment of HCC.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results